हिंदी में पढ़ें
Income Tax Calculator
Personal Loan Calculator
Car Loan Calculator
Home Loan Calculator
MF Returns Calculator
Sun Pharma News
Ganesh Chaturthi Special Stock Picks: Invest in THESE 6 Vighnaharta shares for good returns; check the LIST, know triggers and targets here
Fri, Sep 10, 2021
On the eve of Ganesh Chaturthi, Market Experts and Analysts have suggested 6 vignaharta shares which can give huge profits and good returns to the investors in a period of one year.
Sun Pharma Quarterly Result: Rs 1444 crore PAT in Q1FY22; stock ends over 10%
Fri, Jul 30, 2021
The pharmaceutical major — Sun Pharma on Friday reported in-line first-quarter results, as expected by the majority of the brokerages, it posted a net profit of Rs 1,444.17 crore for the June-ended quarter of the financial year 2021-22, as compared to a net loss of Rs 1,655.6 crore in the same period last year.
Q4 Results: Sun Pharma declines near 4% amid profit-booking – Check what brokerages have to say
Fri, May 28, 2021
Amid profit booking and lower-than-expected quarter-four estimates, Sun Pharma declined around four per cent to Rs 673 per share at around 2:30 pm on the BSE intraday trade on Friday. The stock is the top laggard in the Nifty Pharma index, which is declined most than its sectoral peers.
Sun Pharma Q4 results PREVIEW: Big jump? Huge profit? What to expect? All details here
Thu, May 27, 2021
Ahead of its fourth-quarter results, the experts predict Sun Pharma to report huge profit year-on-year basis. In this regard, Zee Business Senior Equity Research Analyst Devanshi Ashar expects the pharma major’s profit to rise over three-fold in the last quarter of fiscal 2020-2021.
Sun Pharma share price: Sharekhan retains Buy recommendation with price target of Rs 700
Fri, Apr 02, 2021
Sharekhan says that Sun Pharma’s specialty business is on the path to improvement and is expected to gain traction. Two of its existing specialty products - Ilumya and Cequa are witnessing a rise in the prescription numbers and the sales have almost doubled over the past year, attributable to a strong growth in the US, while expansion in Europe and strengthening presence in Japan have also supported the growth
Now, Sun Pharma, Cipla, Cadila Healthcare, Torrent Pharma, DRL, Eris Life are key stocks to watch
Tue, Dec 15, 2020
Among the top 30 companies Mylan clocked the highest growth of 144% for November followed by Glenmark Pharma(+11%), IPCA Labs (+10%) and Ajanta Pharma(+10%) clocking double digit growth while Novartis, Micro, Indoco Remedies, FDC & Mankind Pharma were impacted the most. With 144% growth for the month (sales of Rs 920 m), Mylan has been the standout performer for the month primarily aided by Rs 540 mn sales contribution from its COVID treatment drug, Desrem. Notably, Desrem was the second largest selling brand in IPM for Nov20. Sun Pharma, Cipla, Cadila Healthcare, Torrent Pharma, DRL, Eris Life were among some local listed players that clocked a single digit growth.
Sun Pharma Share Price: Specialty business is witnessing improved traction
Tue, Dec 15, 2020
Sun Pharma Specialty business is witnessing improved traction. Pick up in the US specialty business coupled with likely traction from a sturdy new product launch pipeline, would fuel the growth of the US business. Moreover, geographic expansion/increasing penetration for specialty portfolios, in markets other than the US, would also aid the growth of specialty portfolios. Healthy growth in chronic therapies along with new launches gaining traction and a possible improvement in acute therapies is likely to fuel growth in the domestic formulations business.
Sun Pharma Share Price Today: All drugs listed - check how they are doing and what is likely to happen
Fri, Dec 11, 2020
Sun Pharmaceutical's efforts around specialty portfolio ramp up are yielding favourable progress as prescription trends around the key products suggest growth on a QoQ basis. Levulan which was significantly below pre COVID levels has broadly normalized but Nirmal Bang says needs to monitor the impact of resurgence in COVID cases. In fact, seeing faint signals of an unfavourable impact of the second COVID wave as trends seems to suggest weakening prescription volumes across product categories in the last week of November.
Stocks to Buy With Anil Singhvi: Sanjiv Bhasin recommends 3 money-making blue chips
Mon, Nov 16, 2020
Mid cap companies are moving strongly due to the strong market momentum, however, corrections will he sharper in these markets, so investors and traders should remain cautious. Consumer, Consumption and Auto themes will see good moves in the markets.
Diwali to Diwali Rocket Shares With Anil Singhvi: Westlife and Sun Pharma to give spectacular returns
Fri, Nov 06, 2020
Two powerful stocks have been revealed that are expected to give spectacular returns on show hosted by Zee Business Managing Editor Anil Singhvi, by Rahul Arora, CEO, Nirmal Bang and Sandeep Wagle, CEO, Sandeep Wagle Advisory Services.
CLSA believes Speciality Products should drive rerating for Sun Pharma
Wed, Nov 04, 2020
Sun Pharma’s Q2 FY21 core PBT beats estimate by 28% driven by healthy revenue growth and cost control. Global specialty product sales rebounded 38% QoQ to U.S. $108 mn with sales of key products Ilymuya, Cequa and Odomzo back at pre Covid-19 levels. CLSA raised their FY21 EPS estimate 39% on back of its big beat Q2 FY21.
Dr Reddy's, Cadila, Cipla, IPCA to Biocon, Jefferies initiates coverage on 11 pharma stocks | all investors need to know
Tue, Oct 27, 2020
Jefferies coverage is winning the long term pharma manufacturing game, as shown by new data presented here.
CLSA Maintains Buy Rating on Sun Pharma, Cadila Healthcare, Torrent Pharma and Abbott India; Outperform on Cipla
Fri, Oct 09, 2020
CLSA believes that fundamentals for the pharma sector in 2020 are much healthier than even in 2015.
Stocks to Buy With Anil Singhvi: Why Sun Pharma, Bandhan Bank are best bets for investors - Sanjiv Bhasin explains
Fri, Aug 21, 2020
Stocks to Buy With Anil Singhvi: Analyst Sanjiv Bhasin today said that Nifty is unlikely to come down to 10,800 levels as per his earlier estimates. He told Zee Business Managing Editor Anil Singhvi that investors must remain cautious and hedge their investments. Investors should protect themselves against all eventualities at all times, the IIFL Director said
Stock Market Today: Sensex tests 38K, Nifty sustains above 11,000 mark; Axis Bank, Sun Pharma Advanced shares gain
Wed, Aug 05, 2020
Stock Market Today: The BSE Sensex shot up 323 points and tested 38,000 mark by touching 38,010 levels. The NSE Nifty also gained 90 points and hit 11,186 mark. Bank Nifty index surged 230 points and hit 21,720 levels.
Stocks in Focus on June 4: BPCL, HDFC Life to Pharma Companies; here are expected newsmakers of the day
Thu, Jun 04, 2020
Stocks in Focus on June 4: BPCL, HDFC Life, Aurobindo Pharma, Sun Pharma, etc. are expected to remain newsmakers throughout the intraday trade session.
Stocks in Focus on November 22: CSB bank, RITES to BHEL; here are the 5 Newsmakers of the Day
Fri, Nov 22, 2019
The market snapped its two-day winning run and ended with modest losses on Thursday, November 21, 2019, but stock-specific movements kept the traders busy throughout the day. But certain stocks came in news after the market was closed for trading purposes.
Anil Singhvi’s Strategy September 6: Market Trend is Neutral; Metal sector is Positive; NBFC is Negative
Fri, Sep 06, 2019
On account of positive global markets, DIIs, neutral F&O and negative FIIs, the short-term trend of the Indian markets will be neutral, says Zee Business Managing Editor Anil Singhvi.
Stocks in Focus on September 6: Sun Pharma, Reliance Industries to Tech Mahindra; here are the 5 Newsmakers of the Day
Fri, Sep 06, 2019
Reliance Industries, Sun Pharmaceutical Industries, Bajaj Finance, L&T Finance Holdings and Tech Mahindra are the top 5 stocks that would remain in focus today.
Anil Singhvi’s Strategy September 4: Market Trend & Sentiment are Negative; Sell Sun Pharma Futures with Stop Loss 445
Wed, Sep 04, 2019
On account of positive DIIs, neutral F&O and negative FIIs, the short-term trend of the domestic Indian markets will continue to be negative, says Zee Business Managing Editor Anil Singhvi.